BioCentury
ARTICLE | Product Development

BMS heeds BIO’s call to ‘walk the talk’

August 13, 2020 3:14 AM UTC

A week after BIO unveiled its BIOEquality initiative, BMS said it is preparing to invest $300 million to increase diversity in clinical trials of its therapies and the representation of Blacks and Latinos at all levels of the company.

Wednesday’s announcement by  Bristol Myers Squibb Co. (NYSE:BMY) represents the largest commitment by a biopharma company since BIO called on companies Aug. 5 to put their pledges on social justice into practice. The trade group’s initiative aims to diversify the biotech workforce and ensure that clinical trials reflect the societies they serve (see “BIO Challenging its Members to Walk the Talk”)...

BCIQ Company Profiles

Bristol Myers Squibb Co.